Tue. 26 Mar 2024, 9:28am ET
Benzinga
Earnings, News
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.22) by 31.82 percent. This is a 87.5 percent decrease over losses of $(0.08) per share from the same period last year. The company reported $4.80 million in sales this quarter.